Search
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedDepending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant … Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.
Synonyms: Metilbromuro de octatropinaMethylphenidate
go.drugbank.com/drugs/DB00422ApprovedInvestigationalWater then permeates through the membrane into the tablet core where the osmotically active polymer excipients expand, allowing methylphenidate to release slowly through the orifice over a period of 6- … In contrast, low doses are found to selectively activate NE and DA neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology,
Products: RITALINA® LA 20 MG CAPSULAS DE LIBERACION PROLONGADADaptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigationaltryptophan covalently bonded to decanoic acid. … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … [A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system.
Orphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Categories: Ethers, Chemically Close to AntihistaminesNylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnTherefore, the FDA has withdrawn nylidrin from the U.S. market [L2286]. … This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system.
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Retifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationalBy blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … cells to promote T cell–mediated cytotoxicity.
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager